Developing tumor models from breast cancer samples

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on creating patient-derived xenografts (PDX) from surgical tumor samples of patients with triple negative or luminal B breast cancer. By utilizing these samples, the research aims to enhance understanding of tumor heterogeneity, therapeutic responses, and mechanisms of tumor resistance. The study specifically targets primitive mammary tumors or those after neoadjuvant treatment, which are less commonly used in PDX development. The goal is to compare the histomolecular profiles of the original tumors with those of the developed PDXs to assess success rates and tumor evolution.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
* Signature of the participation consent to the study,
* Affiliation to a social security scheme
* Major woman with:

  * metastatic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of neoadjuvant treatment
  * metaplastic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, treated by primary surgery with a tumor size of at least 15 mm on the specimen.
  * an inflammatory TN breast cancer (T4d), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
  * non-metaplastic or inflammatory TN breast cancer, histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
  * Luminal B breast cancer (LB), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
  * histologically proven metastatic TN or metastatic breast cancer with an operable metastasis whose residual size, after chemotherapy, is at least 10 mm on the specimen. Residual metastasis will be at least 15 mm on imaging.
* Patients in a metastatic situation can be included regardless of the therapeutic line.

Exclusion Criteria:

* Pregnant woman
* Patient deprived of liberty by court or administrative decision
* In neoadjuvant situation: no neoadjuvant treatment by radiotherapy or hormone therapy
* Refusal to participate in the study

Where it's running

• Centre Jean PERRIN
  Clermont-Ferrand, Puy-de-Dôme, France Recruiting

Study contacts

• Principal investigator: Xavier DURANDO, Professor — Centre Jean Perrin
• Study coordinator: Judith PASSILDAS, PhD
• Email: judith.passildas@clermont.unicancer.fr
• Phone: +33463663337

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• Negative pressure wound therapy after mastectomy

  This study tests whether a negative pressure dressing after mastectomy reduces fluid build‑up and common wound complications in women with breast cancer.

  Recruiting Dalarna County Council, Sweden · Falun · NCT07607366

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• Conformal ablative radiotherapy for older women with localized ER-positive, HER2-negative breast cancer choosing non-surgical care

  This study will test whether five focused SABR treatments can control ER-positive, HER2-negative breast tumors up to 5 cm in women aged 65 and older who are opting for non-surgical management.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas and 1 other locations · NCT07242118

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.